Avantor, Inc. (NYSE:AVTR) was recently dropped from the FTSE All-World Index, following a wave of positive investor attention toward U.S. pharmaceutical stocks due to government policy changes.

This shift was driven by the introduction of a 100 percent tariff on imported branded pharmaceuticals and reports of regulatory agreements aimed at lowering domestic drug costs, which have increased the appeal of domestic suppliers like Avantor.

We'll explore how recent trade tariffs positioning Avantor as a more competitive domestic supplier may impact its overall investment outlook.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 32 companies in the world exploring or producing it. Find the list for free.

To be a shareholder in Avantor today is to believe that government tariffs and shifting pharmaceutical policy could help domestic suppliers seize a greater share of industry demand, counterbalancing recent revenue pressures. The newly imposed 100 percent tariff on imported branded pharmaceuticals may boost Avantor’s appeal as a US-based supplier, but doesn’t substantially change the near-term risk: ongoing margin pressures due to aggressive competition and lower organic growth guidance remain front and center.

Among recent company developments, Avantor’s revised guidance for full-year 2025 organic revenue growth, lowered to between negative 2 percent and flat, remains particularly relevant. Even as policy changes create new competitive openings, persistent headwinds in end-market demand, especially within bioprocessing and laboratory solutions, continue to weigh on the company's investment narrative.

On the other hand, investors should be aware of how persistent margin compression could...

Read the full narrative on Avantor (it's free!)

Avantor's narrative projects $7.2 billion revenue and $461.3 million earnings by 2028. This requires 2.5% yearly revenue growth and a $226.1 million earnings decrease from $687.4 million currently.

Uncover how Avantor's forecasts yield a $14.12 fair value, a 3% upside to its current price.

Three fair value estimates from the Simply Wall St Community range widely from US$14.12 to US$46.76 per share. With this diversity in opinion, keep in mind that ongoing margin pressures highlighted recently may play a significant role in shaping the company’s earnings trajectory, consider several viewpoints before making conclusions.

Explore 3 other fair value estimates on Avantor - why the stock might be worth just $14.12!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Our free Avantor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Avantor's overall financial health at a glance.

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Find companies with promising cash flow potential yet trading below their fair value.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AVTR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com